Gargi Vora, MD
Ophthalmology · New Haven, CTNPI 1598993743
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.8% of the total across 190 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Dompe US, Inc. accounts for 89.9% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $6,886, more than ten times the $100 reported in 2022. Among ophthalmology clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 190 payments — averaging $37.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dompe US, Inc.$6K
- Alcon$603
- Carl Zeiss Meditec USA, Inc.$100
- Carl Zeiss Meditec Cataract Technology Inc.$19
What the payments were for
- Travel & lodging$5207%
- Food & beverage$6,66693%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dompe US, Inc. | 185 | $6,463 |
| Alcon | 3 | $603 |
| Carl Zeiss Meditec USA, Inc. | 1 | $100 |
| Carl Zeiss Meditec Cataract Technology Inc. | 1 | $19 |
How this compares
$7,186 in reported general payments places this provider in the 90th percentile of 279 ophthalmology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 47 | $39,664 |
| Restasis MultidoseCyclosporine | 59 | $38,031 |
| Cyclosporine | 69 | $32,554 |
| XiidraLifitegrast | 21 | $14,750 |
| Prednisolone Acetate | 333 | $8,781 |
| MoxifloxacinMoxifloxacin Hcl | 228 | $4,338 |
| Loteprednol Etabonate | 24 | $2,927 |
| Travoprost | 14 | $1,798 |
| Ketorolac Tromethamine | 117 | $1,561 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 25 | $886 |
| Latanoprost | 112 | $876 |
| Doxycycline Hyclate | 12 | $254 |
| ErythromycinErythromycin Base | 17 | $226 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 20 | $187 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 16 | $131 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in New Haven
- Amir CohenNew Haven$266K
- Paul KangNew Haven$40K
- Brian HaflerNew Haven$15K
- James WeiszNew Haven$14K
- Kristen NwanyanwuNew Haven$12K
- Lucian del PrioreNew Haven$9K
- James TsaiNew Haven$7K
- Wayne LarrisonNew Haven$5K
- Sara NetterNew Haven$3K
- John HuangHartford$267K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.